Anabolic bone accruement through osteogenic differentiation is important for the maintenance of physiological bone mass and often disrupted in various inflammatory diseases. Epigallocatechin-3-gallate, as an antioxidant and anti-inflammatory agent, has been suggested for potential therapeutic use in this context, possibly by the inhibition of bone resorption as well as the enhancement of bone formation through directly activating osteoblast differentiation. However, the reported effects of epigallocatechin-3-gallate modulating osteoblast differentiation are mixed, and the underlying molecular mechanism is still elusive. Moreover, there is limited information regarding the effects of epigallocatechin-3-gallate on osteogenic potential of mesenchymal stem cell in inflammation. Here, we examined the in vitro osteogenic differentiation of human mesenchymal stem cells. We found that the cell viability and osteoblast differentiation of human bone marrow-derived mesenchymal stem cells are significantly inhibited by inflammatory cytokine TNFα treatment. Epigallocatechin-3-gallate is able to enhance the cell viability and osteoblast differentiation of mesenchymal stem cells and is capable of reversing the TNFα-induced inhibition. Notably, only low doses of epigallocatechin-3-gallate have such benefits, which potentially act through the inhibition of NF-κB signaling that is stimulated by TNFα. These data altogether clarify the controversy on epigallocatechin-3-gallate promoting osteoblast differentiation and further provide molecular basis for the putative clinical use of epigallocatechin-3-gallate in stem cell-based bone regeneration for inflammatory bone loss diseases, such as rheumatoid arthritis and prosthetic osteolysis.
BaumRGravalleseEM. Impact of inflammation on the osteoblast in rheumatic diseases. Curr Osteoporos Rep2014; 12: 9–16.
2.
De BenedettiFRucciNDel FattoreAPeruzziBParoRLongoMVivarelliMMuratoriFBerniSBallantiPFerrariSTetiA. Impaired skeletal development in interleukin-6-transgenic mice: a model for the impact of chronic inflammation on the growing skeletal system. Arthritis Rheum2006; 54: 3551–63.
3.
RedlichKSmolenJS. Inflammatory bone loss: pathogenesis and therapeutic intervention. Nat Rev Drug Discov2012; 11: 234–50.
4.
SelaJApplebaumJUretzkyG. Osteogenesis induced by bone matrix is inhibited by inflammation. Biomater Med Devices Artif Organs1986; 14: 227–37.
5.
ThakkerMMZhangJSiresBS. Chronic inflammation from polycarbonate motility peg inhibits osteogenesis in a human hydroxyapatite orbital implant. Ophthal Plast Reconstr Surg2005; 21: 399–401.
6.
GoldringSRGoldringMB. Eating bone or adding it: the Wnt pathway decides. Nat Med2007; 13: 133–4.
7.
WalshNCGravalleseEM. Bone remodeling in rheumatic disease: a question of balance. Immunol Rev2010; 233: 301–12.
8.
HofbauerLCSchoppetM. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA2004; 292: 490–5.
9.
JimiEAokiKSaitoHD'AcquistoFMayMJNakamuraISudoTKojimaTOkamotoFFukushimaHOkabeKOhyaKGhoshS. Selective inhibition of NF-kappa B blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo. Nat Med2004; 10: 617–24.
10.
RomasESimsNAHardsDKLindsayMQuinnJWRyanPFDunstanCRMartinTJGillespieMT. Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis. Am J Pathol2002; 161: 1419–27.
11.
UccelliAMorettaLPistoiaV. Mesenchymal stem cells in health and disease. Nat Rev Immunol2008; 8: 726–36.
12.
AugelloATassoRNegriniSMCanceddaRPennesiG. Cell therapy using allogeneic bone marrow mesenchymal stem cells prevents tissue damage in collagen-induced arthritis. Arthritis Rheum2007; 56: 1175–86.
13.
KitaoriTItoHSchwarzEMTsutsumiRYoshitomiHOishiSNakanoMFujiiNNagasawaTNakamuraT. Stromal cell-derived factor 1/CXCR4 signaling is critical for the recruitment of mesenchymal stem cells to the fracture site during skeletal repair in a mouse model. Arthritis Rheum2009; 60: 813–23.
14.
KramperaMPizzoloGApriliGFranchiniM. Mesenchymal stem cells for bone, cartilage, tendon and skeletal muscle repair. Bone2006; 39: 678–83.
15.
ChenFHTuanRS. Mesenchymal stem cells in arthritic diseases. Arthritis Res Ther2008; 10: 223–223.
16.
GonzalezMAGonzalez-ReyERicoLBuscherDDelgadoM. Treatment of experimental arthritis by inducing immune tolerance with human adipose-derived mesenchymal stem cells. Arthritis Rheum2009; 60: 1006–19.
17.
EdwardsCK3rdBendeleAMReznikovLIFantuzziGChlipalaESLiLMoldawerLLMountzJDLiYYDinarelloCA. Soluble human p55 and p75 tumor necrosis factor receptors reverse spontaneous arthritis in transgenic mice expressing transmembrane tumor necrosis factor alpha. Arthritis Rheum2006; 54: 2872–85.
18.
AloeLProbertLKolliasGBracci-LaudieroLSpillantiniMGLevi-MontalciniR. The synovium of transgenic arthritic mice expressing human tumor necrosis factor contains a high level of nerve growth factor. Growth Factors1993; 9: 149–55.
19.
RedlichKHayerSRicciRDavidJPTohidast-AkradMKolliasGSteinerGSmolenJSWagnerEFSchettG. Osteoclasts are essential for TNF-alpha-mediated joint destruction. J Clin Invest2002; 110: 1419–27.
20.
LamJTakeshitaSBarkerJEKanagawaORossFPTeitelbaumSL. TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest2000; 106: 1481–8.
21.
AzumaYKajiKKatogiRTakeshitaSKudoA. Tumor necrosis factor-alpha induces differentiation of and bone resorption by osteoclasts. J Biol Chem2000; 275: 4858–64.
22.
RitchlinCTHaas-SmithSALiPHicksDGSchwarzEM. Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Invest2003; 111: 821–31.
JilkaRLWeinsteinRSBellidoTParfittAMManolagasSC. Osteoblast programmed cell death (apoptosis): modulation by growth factors and cytokines. J Bone Miner Res1998; 13: 793–802.
25.
YamashitaMOtsukaFMukaiTOtaniHInagakiKMiyoshiTGotoJYamamuraMMakinoH. Simvastatin antagonizes tumor necrosis factor-alpha inhibition of bone morphogenetic proteins-2-induced osteoblast differentiation by regulating Smad signaling and Ras/Rho-mitogen-activated protein kinase pathway. J Endocrinol2008; 196: 601–13.
26.
GilbertLHeXFarmerPBodenSKozlowskiMRubinJNanesMS. Inhibition of osteoblast differentiation by tumor necrosis factor-alpha. Endocrinology2000; 141: 3956–64.
27.
GilbertLHeXFarmerPRubinJDrissiHvan WijnenAJLianJBSteinGSNanesMS. Expression of the osteoblast differentiation factor RUNX2 (Cbfa1/AML3/Pebp2alpha A) is inhibited by tumor necrosis factor-alpha. J Biol Chem2002; 277: 2695–701.
28.
VincentCFindlayDMWelldonKJWijenayakaARZhengTSHaynesDRFazzalariNLEvdokiouAAtkinsGJ. Pro-inflammatory cytokines TNF-related weak inducer of apoptosis (TWEAK) and TNFalpha induce the mitogen-activated protein kinase (MAPK)-dependent expression of sclerostin in human osteoblasts. J Bone Miner Res2009; 24: 1434–49.
29.
LiQVermaIM. NF-kappaB regulation in the immune system. Nat Rev Immunol2002; 2: 725–34.
30.
HigdonJVFreiB. Tea catechins and polyphenols: health effects, metabolism, and antioxidant functions. Crit Rev Food Sci Nutr2003; 43: 89–143.
31.
SurhYJChunKSChaHHHanSSKeumYSParkKKLeeSS. Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: down-regulation of COX-2 and iNOS through suppression of NF-kappa B activation. Mutat Res2001; 480–481: 243–68.
32.
ShenCLYehJKCaoJJWangJS. Green tea and bone metabolism. Nutr Res2009; 29: 437–56.
33.
DevineAHodgsonJMDickIMPrinceRL. Tea drinking is associated with benefits on bone density in older women. Am J Clin Nutr2007; 86: 1243–7.
34.
JohnellOGullbergBKanisJAAllanderEElfforsLDequekerJDilsenGGennariCLopes VazALyritisGMazzuoliGMiravetLPasseriMCanoPRRapadoARibotC. Risk factors for hip fracture in European women: the MEDOS Study. Mediterranean Osteoporosis Study. J Bone Miner Res1995; 10: 1802–15.
35.
ChenCHHoMLChangJKHungSHWangGJ. Green tea catechin enhances osteogenesis in a bone marrow mesenchymal stem cell line. Osteoporos Int2005; 16: 2039–45.
36.
ValiBRaoLGEl-SohemyA. Epigallocatechin-3-gallate increases the formation of mineralized bone nodules by human osteoblast-like cells. J Nutr Biochem2007; 18: 341–7.
37.
KamonMZhaoRSakamotoK. Green tea polyphenol (-)-epigallocatechin gallate suppressed the differentiation of murine osteoblastic MC3T3-E1 cells. Cell Biol Int2010; 34: 109–16.
38.
MahYJSongJSKimSOLeeJHJeonMJungUWMoonSJKimJHChoiHJ. The effect of epigallocatechin-3-gallate (EGCG) on human alveolar bone cells both in vitro and in vivo. Arch Oral Biol2014; 59: 539–49.
39.
YagiHTanJTuanRS. Polyphenols suppress hydrogen peroxide-induced oxidative stress in human bone-marrow derived mesenchymal stem cells. J Cell Biochem2013; 114: 1163–73.
40.
GerstenfeldLCChoTJKonTAizawaTCrucetaJGravesBDEinhornTA. Impaired intramembranous bone formation during bone repair in the absence of tumor necrosis factor-alpha signaling. Cells Tissues Organs2001; 169: 285–94.
41.
GerstenfeldLCChoTJKonTAizawaTTsayAFitchJBarnesGLGravesDTEinhornTA. Impaired fracture healing in the absence of TNF-alpha signaling: the role of TNF-alpha in endochondral cartilage resorption. J Bone Miner Res2003; 18: 1584–92.
42.
HessKUshmorovAFiedlerJBrennerREWirthT. TNFalpha promotes osteogenic differentiation of human mesenchymal stem cells by triggering the NF-kappaB signaling pathway. Bone2009; 45: 367–76.
43.
KatiyarSKMatsuiMSElmetsCAMukhtarH. Polyphenolic antioxidant (-)-epigallocatechin-3-gallate from green tea reduces UVB-induced inflammatory responses and infiltration of leukocytes in human skin. Photochem Photobiol1999; 69: 148–53.
44.
TominariTMatsumotoCWatanabeKHirataMGrundlerFMMiyauraCInadaM. Epigallocatechin gallate (EGCG) suppresses lipopolysaccharide-induced inflammatory bone resorption, and protects against alveolar bone loss in mice. FEBS Open Bio2015; 5: 522–7.
45.
MorinobuABiaoWTanakaSHoriuchiMJunLTsujiGSakaiYKurosakaMKumagaiS. (-)-Epigallocatechin-3-gallate suppresses osteoclast differentiation and ameliorates experimental arthritis in mice. Arthritis Rheum2008; 58: 2012–8.
46.
ChoiJHRheeIKParkKYKimJKRheeSJ. Action of green tea catechin on bone metabolic disorder in chronic cadmium-poisoned rats. Life Sci2003; 73: 1479–89.
47.
ShenCLWangPGuerrieriJYehJKWangJS. Protective effect of green tea polyphenols on bone loss in middle-aged female rats. Osteoporos Int2008; 19: 979–90.
48.
JinPWuHXuGZhengLZhaoJ. Epigallocatechin-3-gallate (EGCG) as a pro-osteogenic agent to enhance osteogenic differentiation of mesenchymal stem cells from human bone marrow: an in vitro study. Cell Tissue Res2014; 356: 381–90.
49.
TakitaHKikuchiMSatoYKubokiY. Inhibition of BMP-induced ectopic bone formation by an antiangiogenic agent (epigallocatechin 3-gallate). Connect Tissue Res2002; 43: 520–3.
50.
ZgheibALamySAnnabiB. Epigallocatechin gallate targeting of membrane type 1 matrix metalloproteinase-mediated Src and Janus kinase/signal transducers and activators of transcription 3 signaling inhibits transcription of colony-stimulating factors 2 and 3 in mesenchymal stromal cells. J Biol Chem2013; 288: 13378–86.
